169674-55-9

Usage

General Description

1H-Indole-2-carboxylic acid, 5-chloro-6-fluoro- is a chemical compound with the molecular formula C9H6ClFNO2. It is a derivative of indole carboxylic acid, with a chlorine atom at the 5th position and a fluorine atom at the 6th position. 1H-Indole-2-carboxylic acid, 5-chloro-6-fluoro- is commonly used in the synthesis of pharmaceuticals and agrochemicals. It exhibits a broad spectrum of biological activities, including anti-inflammatory, anti-viral, and anti-tumor properties. It is also used as a building block in the development of various drug candidates. Additionally, its unique structure and reactivity make it a valuable tool in organic synthesis and medicinal chemistry research.

Upstream product

• 169674-14-0 methyl 5-chloro-6-fluoro-1H-indole-2-carboxylate 
• 169674-53-7 methyl α-azido-3-chloro-4-fluorocinnamate 

Downstream Products

• 169674-57-1 5-chloro-6-fluoro-1H-indole 

Relevant academic research and scientific papers

Syntheses of 4-(indole-3-yl)quinazolines - A new class of epidermal growth factor receptor tyrosine kinase inhibitors

The epidermal growth factor (EGF) family of membrane receptors has been identified as a key element in the complex signaling network that is utilized by various classes of cell-surface receptors. The synthesis and pharmacological results of 4-(indole-3-yl)quinazolines are described. The synthesized compounds are new high potent EGFR-tyrosine kinase inhibitors with excellent cytotoxic properties at different cell lines. Furthermore the 4-(indole-3-yl)quinazolines show some tendencies to inhibit the HER-2 TK, too. Moreover this substance class has remarkable strong fluorescence properties.

A novel synthesis of EGFR-tyrosine-kinase inhibitors with 4-(indol-3-yl)quinazoline structure

(Chemical Equation Presented) The epidermal growth factor (EGF) family of membrane receptors has been identified as a key element in the complex signaling network that is utilized by various classes of cell-surface receptors. A new synthetic pathway of 4-(indol-3-yl)quinazolines 15 and 16 is described using cross coupling reactions with quinazoline- and indole moieties. The synthesized compound 15 is a new dual and high potent EGFR- and HER-2-tyrosine kinase inhibitor with excellent cytotoxic properties at different cell lines. Furthermore this substance class shows remarkably strong fluorescence.

SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND THEIR USE

The invention relates to the use of substituted 4-(indol-3-yl)quinazolines or one of their salts for inhibiting proteinase activity, in particular the EGF receptor-specific tyrosine protein kinase, for treating tumours, osteoporosis or proliferative epidermal diseases, in addition to novel substituted 4-(indol-3-yl)quinazolines or one of their salts and to a method for producing said substances. The invention also relates to the use of substituted 4-(indol-3- yl)quinazoline derivatives or one of their salts for inhibiting protein kinase activity, in particular for crop protection in the development of fungicidal, herbicidal or insecticidal active ingredients.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.